EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials

Naiem Issa, Anna Campanati, André Carvalho, Eingun Song, Alexander Zink, Leonor Avó, Sarah Kavanagh, Nicolas Hurni, Vimal Prajapati

SKIN The Journal of Cutaneous Medicine · 11.05.2026 · 10 (3) · s773

DOI: 10.25251/h6t2hj68 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 11.05.2026. Verfasst von Naiem Issa und 8 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bimekizumab (BKZ) has demonstrated rapid, sustained efficacy in moderate to severe plaque psoriasis, with many patients achieving skin responses at Week (Wk)4, after one dose.1 While early clinical response is important to patients, as demonstrated using a cross-sectional survey by Gorelick et al., disease chronicity makes long-term durability crucial for both patients and clinicians.2,3 Here, we examine the maintenance of clinical and quality of life (QoL) outcomes over 4 years (yrs) in patients achieving early skin responses with BKZ. Procedure/study Data were pooled from the 52/56-wk phase 3 trials BE VIVID/BE SURE/BE READY and their 144-wk open-label extension (OLE), BE BRIGHT.1,4–7 Patients received BKZ 320mg every 4 wks (Q4W) to Wk16, then BKZ Q4W or Q8W into the OLE (BKZ Total). All received BKZ Q8W from OLE Wk100/104 or next scheduled visit. A subgroup received BKZ Q4W to Wk16 then Q8W thereafter (BKZ Q4W/Q8W; approved dosing regimen for most patients with psoriasis).8 Maintenance of ≥75/≥90/100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100) and Dermatology Life Quality Index (DLQI) 0/1 was assessed through Wk196/200 (Yr4) in Wk4 PASI 75/90 responders. Patients discontinuing treatment due to lack of efficacy/treatment-related adverse events were considered non-responders at subsequent timepoints; multiple imputation was used for all other missing data.

Results

Overall, 771 patients received BKZ continuously and entered the OLE (BKZ Total); 592 (76.8%)/331 (42.9%) were Wk4 PASI 75/90 responders (BKZ Q4W/Q8W [N=197]: 158 [80.2%]/79 [40.1%]). Baseline characteristics were similar between Wk4 PASI 75/90 responders and the overall population. In the BKZ Total group, 95.3% of Wk4 PASI 75 responders maintained PASI 75 to Yr4. In BKZ Total Wk4 PASI 75 responders, PASI 90/PASI 100/DLQI 0/1 responses increased from Wk4 (55.9%/20.8%/41.3%) to Wk16 (95.2%/71.3%/73.6%) and were maintained to Yr4 (87.6%/67.5%/78.6%). Among BKZ Total Wk4 PASI 90 responders, 95.6%/89.2% maintained PASI 75/90 responses to Yr4. In Wk4 PASI 90 responders, PASI 100/DLQI 0/1 responses increased from Wk4 (37.2%/49.7%) to Wk16 (79.7%/79.4%) and were maintained to Yr4 (73.2%/80.7%). Responses were similar in the BKZ Q4W/Q8W subgroup.

Conclusion

Patients with early skin improvement after 4 wks of bimekizumab maintained or improved high skin and QoL responses through 4 yrs, providing insight for clinicians and patients that bimekizumab may provide both rapid and durable psoriasis disease control.

Zitieren

APA

Issa, N., Campanati, A., Carvalho, A., Song, E., Zink, A., Avó, L., Kavanagh, S., Hurni, N., & Prajapati, V. (2026). Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 10(3), s773. https://doi.org/10.25251/h6t2hj68

Vancouver

Issa N, Campanati A, Carvalho A, Song E, Zink A, Avó L, et al. Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 2026;10(3):s773. doi:10.25251/h6t2hj68

BibTeX
@article{Issa2026,
  author = {Issa, Naiem and Campanati, Anna and Carvalho, André and Song, Eingun and Zink, Alexander and Avó, Leonor and Kavanagh, Sarah and Hurni, Nicolas and Prajapati, Vimal},
  title = {Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {3},
  pages = {s773},
  doi = {10.25251/h6t2hj68}
}
Kostenlos starten →